CEDAR KNOLLS, N.J.,
Nov. 6, 2018 /PRNewswire/ -- MYOS
RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ:MYOS), a
biotherapeutics and bionutrition company and the owner of
Fortetropin®, a proprietary bioactive composition
derived from fertilized egg yolk that helps build lean muscle,
announced today that it will provide financial results for the
third quarter of 2018 on Tuesday, November
13 after the market closes.
The company will host a conference call on Thursday, November 15, 2018 at 10:30 am ET, at which time MYOS Chief Executive
Officer Joseph Mannello will provide
commentary on earnings results for the third quarter and provide an
update on the business.
Conference Call Details:
Call
Date/Time:
|
Thursday, November
15, 2018 at 10:30 am ET
|
Call Title:
|
MYOS RENS Technology
Third Quarter 2018 Results Conference Call
|
Dial In:
|
877-407-4019 from the
U.S.; international callers may telephone 201-689-8337,
approximately 15 minutes before the call
|
A digital replay will be available by telephone approximately
two hours after the completion of the call until February 9, 2019 and may be accessed by dialing
877-660-6853 from the U.S. or 201-612-7415 for international
callers, using the Conference ID# 13684940
This call will be simultaneously webcast. The webcast will be
available on the MYOS website, www.myosrens.com, in the "Investor
Relations" section. The webcast will be archived and available at
the same web address for two weeks following the call.
About MYOS RENS Technology Inc.
MYOS RENS
Technology Inc. (Nasdaq: MYOS), "The Muscle Company®",
is a Cedar Knolls, NJ-based
bionutrition company that develops and markets products that
improve muscle health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size and lean body mass in conjunction with
resistance training. MYOS believes Fortetropin has the potential to
redefine existing standards of physical health and wellness. For
more information, please visit www.MYOSRENS.com.
Forward-Looking Statements
Any statements in
this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the successful launch of our products,
including Qurr®, Yolked®, MYOS Enteral
Nutrition Formula and MYOS Canine Muscle Formula™ products, the
success of our research and development, including the clinical
studies described above, the results of the clinical evaluation of
Fortetropin® and its effects, the ability to enter into new
partnership opportunities and the success of our existing
partnerships, the ability to generate the forecasted revenue stream
and cash flow from sales of our products, the ability to continue
increasing our revenue and gross profit margins, the ability to
achieve a sustainable, profitable business, the effect of economic
conditions, the ability to protect our intellectual property
rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, and other factors discussed from time to
time in our filings with the Securities and Exchange
Commission. We undertake no obligation to update or revise any
forward-looking statement for events or circumstances after the
date on which such statement is made except as required by
law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-announces-the-date-for-the-release-of-third-quarter-2018-results-conference-call-and-webcast-300745193.html
SOURCE MYOS RENS Technology